In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death.

Vassilopoulos, Athanasios; Mylonakis, Eleftherios

Vassilopoulos, Athanasios; Mylonakis, Eleftherios.

Afiliação

Vassilopoulos A; Rhode Island Hospital and The Miriam Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA (A.V., E.M.).
Mylonakis E; Rhode Island Hospital and The Miriam Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA (A.V., E.M.).

Ann Intern Med ; 175(6): JC63, 2022 06.

Article em En | MEDLINE | ID: mdl-35667068

ABSTRACT

ABSTRACT

SOURCE CITATION Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;3861397-408. 35172054.

Assuntos

Tratamento Farmacológico da COVID-19; Adulto; Hospitalização; Humanos; Ritonavir/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google